Maribavir Drug Asset Due Diligence Report 2026

This Maribavir Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Maribavir can convert its Small molecule drug profile and UL97 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Maribavir (query alias: maribavir)
Modality / target	Small molecule drug; UL97; UL97 inhibitors, DNA synthesis inhibitors
Highest global status	Approved
Originator	Takeda Pharmaceutical Co., Ltd.
Active developers	Takeda Pharmaceuticals Korea Co., Ltd., Takeda Pharmaceuticals International AG, T’s Pharma Co., Ltd.

The MCP disease footprint includes Cytomegalovirus Infections, Cytomegalovirus viremia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07511127	Phase 3	Recruiting	218	The incidence of recurrent CMV infection
NCT07014319	Phase 2	Recruiting	20	Rate to Achieve CMV DNA Titer Reduction to < 500 IU/mL
CTR20253525	Not Applicable	已完成	40	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

HIGH EFFICACY AND MANAGEABLE SAFETY OF MARIBAVIR AS FIRST LINE TREATMENT FOR CMV INFECTION IN ALLO-HSCT RECIPIENTS: A MULTICENTER, RETROSPECTIVE, CONTROLLED COHORT STUDY

Not Applicable; n=88; evaluation: Positive. Reported fields: 14-day clearance(intention-to-treat analysis) = 60.61 % ; 14-day clearance(intention-to-treat analysis) = 81.82 %

FIRST-LINE MARIBAVIR TREATMENT FOR PATIENTS WITH CMV INFECTION INTOLERANT TO CONVENTIONAL ANTIVIRAL DRUGS

Not Applicable; n=12; evaluation: Positive. Reported fields: CMV reinfections = 4.0 pts

Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

Phase 4; n=70; evaluation: not stated. Reported fields: -; Clinical Significant Leukopenia = 1 Participants ; Clinical Significant Leukopenia = 8 Participants

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Maribavir addresses Cytomegalovirus Infections, Cytomegalovirus viremia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2003-08-11	ViroPharma Licenses Rights from GlaxoSmithKline for Product Candidate for Cytomegalovirus (CMV) in Immunocompromised Patients	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Maribavir compositions and uses thereof”. The milestone feed surfaced a patent-application signal described as “Method of preparing maribavir”. The milestone feed surfaced a patent-application signal described as “Nanosuspension of maribavir and preparation method thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO